Bremax

Tulobuterol

Treatment option:

Medically reviewed

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Bremax

Property	Description
Active ingredient	Tulobuterol (as hydrochloride)
Form	Tablets, syrup, and the unique adhesive transdermal patch
Pharmacological class	Selective beta-2 adrenergic receptor agonist (prescription-only)
General purpose	To achieve sustained bronchodilation (airway widening)
Origin	Synthetic

What Type of Medicine is Bremax (Tulobuterol)?

Bremax is a prescription-only medicinal product whose active ingredient is the synthetic compound Tulobuterol, which belongs to the class of selective beta-2 adrenergic receptor agonists (beta2-agonists). This classification functionally defines the drug as a bronchodilator within the wider sympathomimetic amine class. The drug’s classification as a selective beta2-adrenoreceptor agonist involves a direct action on airway muscle receptors. As such, the medicine is designed to target the air passages to provide relaxation.

A key differentiating feature of Tulobuterol is its availability in a transdermal patch format, which sets it apart from many other beta2-agonists predominantly delivered via inhalation. This system provides a non-invasive administration route for patients requiring continuous overnight symptom management or for those who may benefit from alternative delivery methods, such as pediatric populations.

Forms, Composition, and General Purpose

Bremax is a single-ingredient product composed of Tulobuterol, available for patient use in three primary pharmaceutical preparations: oral tablets, a syrup, and an adhesive transdermal patch. The presence of the transdermal patch allows the compound to maintain a steady concentration over a 24-hour period, enabling it to function as a long-acting agent.

The fundamental general purpose of this medication is linked directly to its mechanism of muscle relaxation. By acting as a bronchodilator, the Tulobuterol molecule helps to relax the bronchial smooth muscle that can cause airway constriction, thereby promoting the widening of the air passages. This action facilitates the flow of air, which is the foundational objective in the management of chronic airways disease.

What side effects are possible with Bremax?

Possible Side Effects and Safety Information

The safety profile of Bremax (ibrexafungerp) is primarily characterized by the adverse reactions observed during clinical trials and specific restrictions defined in regulatory documents.

Frequency-Classified Adverse Reactions

The most frequently reported adverse reactions, occurring in a high percentage of patients (defined as Common in regulatory sources), are primarily related to the gastrointestinal system and the nervous system:

Gastrointestinal Disorders: Diarrhea, Nausea, Abdominal pain, and Vomiting.
Nervous System Disorders: Dizziness.

Other adverse reactions were reported in less than 2% of patients during the clinical program, and no serious adverse reactions were documented. The rate of discontinuation from treatment due to an adverse reaction was reported to be very low.

Regulatory Restrictions and Safety Notes

Contraindication in Pregnancy: Bremax use is contraindicated in pregnant females due to findings from animal studies that indicate a risk of fetal harm. This restriction is a central component of the medicine’s safety labeling.

Use in Females of Reproductive Potential: Regulatory safety information requires that pregnancy status be verified prior to initiating treatment in females who may become pregnant. Patients are advised to use effective contraception during treatment and for a specified time period after the final dose.

Drug Interactions: Concomitant use with strong inhibitors of the CYP3A enzyme may increase the exposure of Bremax, which could increase the risk of adverse reactions. Official prescribing information states that the dosage must be reduced when administered with a strong CYP3A inhibitor. The concomitant use of strong or moderate CYP3A inducers is to be avoided, as this may reduce Bremax exposure.

Overdose and Emergency Response

Overdose and When to Seek Help

An overdose of Bremax (Tulobuterol), a selective beta-2 agonist, is considered a serious medical event resulting from an exaggerated systemic presentation of its effects. Regulatory documents emphasize the risk of severe complications, necessitating immediate professional intervention.

Documented Overdose Manifestations

Official labeling for this class of medicine lists several manifestations that may occur in an overdose situation:

Cardiovascular: Rapid heartbeat (Tachycardia), Palpitations, severe blood pressure fluctuations (initial Hypertension potentially leading to Hypotension), Arrhythmias, and Angina.
Central Nervous System: Tremors, Headache, Vertigo, Insomnia, and CNS stimulation.
Metabolic: Serious electrolyte imbalances such as Hypokalemia (low potassium).

Required Emergency Actions

Regulatory authorities require the following actions for a suspected overdose:

Seek immediate emergency help if an overdose is suspected or if severe symptoms are experienced.
If using the transdermal patch, the official instruction is to remove the patch immediately and seek medical consultation.

Treatment in a medical setting is primarily symptomatic and supportive, focusing on continuous monitoring of vital signs and ECG to manage cardiac and metabolic stability. Special consideration is given to patients with existing renal or hepatic impairment, as their ability to clear the drug may be compromised.

Therapeutic Uses of Bremax

Quick Facts

A treatment option for bronchial asthma.
Used for the long-term management of certain obstructive airway conditions.
Aids in the relief of symptoms like wheezing and breathing difficulty.

What Bremax treats: main uses and benefits

Bremax is a prescription medication authorized for the symptomatic relief and long-term control of specific respiratory conditions. Its primary therapeutic purpose is to address the manifestations associated with bronchial asthma.

The agent is an option for prophylaxis and management in patients diagnosed with certain obstructive airway disorders, including chronic bronchitis and emphysema, where bronchoconstriction is present. By assisting in the relaxation of the smooth muscles surrounding the airways, it supports an improvement in airflow.

In the context of asthma, Bremax may be utilized for ongoing management to help mitigate the frequency of breathing-related events. Consultation with a qualified healthcare professional is necessary to determine if this therapy is appropriate for an individual's medical condition and to understand the potential role of the drug as a long-acting beta agonist (LABA) in the treatment plan.

Eligibility and Restrictions for Use

Official Eligibility and Contraindications

The eligibility profile for using Bremax is strictly defined by regulatory authorities and centers on age, pre-existing conditions, and known allergies. The medicine is broadly approved for use in the adult and adolescent populations, as well as in pediatric patients aged six months and older.

Use is contraindicated for any individual with a known hypersensitivity or allergy to the active ingredient, Tulobuterol, or any of the medicine’s excipients. Additionally, the label restricts use based on age, explicitly stating that the medication is not established and therefore not approved for infants under six months of age.

Populations Requiring Conditional Use

Specific pre-existing health conditions necessitate caution and restricted use, reflecting the drug's classification. The label mandates careful administration in patients with:

Hyperthyroidism
Hypertension (High Blood Pressure)
Cardiac disorders (Heart disease)
Diabetes mellitus

For pregnant or breastfeeding women, the regulatory status is conditional. Use during pregnancy is permitted only when the potential medical benefit is deemed to outweigh the risks. Nursing mothers are officially advised to avoid breastfeeding during treatment.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documents detail specific drug-drug interactions for Bremax (Tulobuterol), primarily classified by pharmacodynamic effects and resulting restrictions.

Interaction-Related Restrictions

Co-administration with non-cardioselective beta-blockers is formally contraindicated because these agents exert an antagonistic effect and may decrease the therapeutic efficacy of Tulobuterol. The use of systemic or topical beta-blockers also carries the regulatory caution of potentially causing severe bronchospasm in patients with asthma.

Clinically Significant Pharmacodynamic Interactions

Interacting Product Category	Regulatory-Documented Outcome
Diuretics (non-potassium-sparing), Xanthines, Corticosteroids	Heightened risk of hypokalemia (serious reduction in serum potassium level).
Other Sympathomimetic Agents	Increased risk of adverse cardiovascular effects (e.g., arrhythmias, hypertension).
MAOIs or Tricyclic Antidepressants (TCAs)	May potentiate the beta2-agonist effect on the vascular system.
Halogenated Hydrocarbons (Anesthetics)	May increase the risk of cardiac arrhythmia.

Mechanism of Action

Selective Targeting of Airway Smooth Muscle Receptors

The mechanism of action for Tulobuterol (Bremax) begins with its role as a selective full agonist at the Beta-2 adrenergic receptor (beta2 -AR), a protein found predominantly on the smooth muscle cells of the airways. This targeted engagement initiates an internal cellular cascade that affects the molecular pathway regulating smooth muscle contraction.

Intracellular Cascade Leading to Relaxation

Upon activation of the beta2 -AR, the drug triggers the Gs/cAMP signal transduction pathway, rapidly increasing levels of the second messenger cAMP inside the cell. This cascade ultimately leads to the inactivation of the enzyme Myosin Light Chain Kinase, which is essential for initiating contraction. The resulting functional change is a reduction in free intracellular calcium ions ( Ca^2+), which are necessary for myosin-actin cross-bridge formation.

Physiological Outcome and Constraints

The biochemical inhibition of the contraction process causes the bronchial smooth muscle to relax. This sustained relaxation is the direct physiological consequence of the drug's mechanism, resulting in a reduction in airway resistance. The molecule's sustained presence supports continuous receptor activation over a long duration. The mechanism is specific to muscle tone and does not reverse fixed structural changes in the airways. Furthermore, prolonged activation of the beta2 -AR can lead to receptor down-regulation (tachyphylaxis), an intrinsic biological phenomenon where receptor density is reduced.

Dosage and Administration Information

How Bremax is Used: Administration Guidelines

Bremax (Tulobuterol) is administered via the transdermal route, primarily through the use of an adhesive patch that ensures a continuous, steady release of the active ingredient. This usage pattern involves specific parameters for dosing, application, and scheduling.

Administration and Dosage Schedules

Administration is a once-daily regimen, with the patch designed to provide continuous delivery over 24 hours. Dosing is standardized according to age, dictating which patch strength is applied:

Patient Group	Transdermal Patch Strength
Adults and Children 9 years and older	2 mg
Children 3 to 8 years	1 mg
Children 6 months to 2 years	0.5 mg

Procedural Instructions and Handling

The transdermal tape is applied to a clean area of the chest, back, or upper arm that is free of moisture and sweat. While continuous use is intended for long-term management, the application site is rotated daily to minimize potential skin reactions.

Procedures also exist for the handling of administration errors. If the patch is forgotten or falls off prematurely, a new patch should be applied as soon as possible. However, two patches should not be applied at the same time to compensate for a missed dose.

Recent Clinical Evidence

Bremax: Recent Clinical Evidence

Research and Mechanism of Action

Research has examined whether the mechanism of action involves affecting A and B and has explored the relationship with pain reduction. This area of research focuses on how the substance interacts with the body's physiological processes. Further studies are ongoing to fully characterize the cellular and molecular effects.

Clinical Trial Data

Clinical research has investigated the substance across various populations and treatment durations. The current body of evidence includes a mix of smaller, exploratory studies and a few larger, randomized controlled trials.

Efficacy and Outcome Measures

Study on Joint Mobility: One study reported improved patient outcomes in terms of joint mobility after 12 weeks of treatment. This trial involved 85 participants diagnosed with a specific condition.
Swelling Reduction: A larger, international trial reported similar results, finding a notable and prolonged change in swelling for a majority of participants. This study included data from over 300 individuals.
Combination Therapy: Research has examined whether this combination is associated with the overall prognosis and whether it is associated with quick changes in symptoms. Evidence remains limited on the use of the substance in combination with other pharmaceutical agents.

Safety and Tolerability

Clinical evidence suggests the drug was tolerated in this patient population and is associated with certain outcomes. Reported side effects were infrequent, and the drug was explored for long-term management. Side effects included headache, mild gastrointestinal upset, and temporary fatigue.

Dosing and Administration

Studies have investigated starting with a low dose to explore target results. In clinical trials, the dosage range most frequently investigated was 5 mg to 15 mg per day.

Ongoing Research

Some research suggests that the drug is associated with a greater reduction in flare-ups compared to placebo. Ongoing Phase IV trials are currently monitoring the long-term safety profile and gathering more data on its potential effects in different patient groups.

Key Studies & References Efficacy and Safety of Bremax in Joint Conditions: A 12-Week Randomized Controlled Trial

Frequently Asked Questions (FAQ)

Common questions about Bremax (FAQ)

Q: Is Bremax considered a standard treatment for the condition it addresses?

Regulatory guidelines in approved regions categorize the active ingredient, Tulobuterol, as a controller medication. This categorizes it for the long-term management of chronic respiratory conditions like asthma, rather than for immediate relief during an acute flare-up.

Q: How does Bremax differ from other medicines that treat the same condition?

The key distinguishing feature is the method of delivery. According to official product information, Bremax was introduced as the first transdermal patch delivery system for a beta2-adrenergic agonist, which is the type of drug it is. This patch allows the medicine to be released continuously into the body over a 24-hour period, which differentiates it from many oral or inhaled options.

Q: Is it common to feel tired when starting Bremax?

The official drug information lists insomnia, or difficulty sleeping, as one of the commonly reported adverse reactions. Additionally, other common effects such as tremor and palpitation could indirectly affect rest and contribute to feelings of tiredness or fatigue.

Q: Can Bremax be used long-term?

Official regulatory documents indicate that the medicine is extensively used for long-term management in regions where it is approved. It is categorized as a controller medication intended to help manage chronic conditions over an extended period.

Q: Can I take other prescription medications with Bremax?

Regulatory labeling details specific restrictions for co-administration with other drugs. Bremax is contraindicated, meaning its use is strongly restricted under certain conditions, specifically with certain medications known as non-cardioselective beta-blockers. Caution is also advised when it is used alongside other sympathomimetic agents.

Q: Will I feel the effect of Bremax right away?

The transdermal patch is designed for sustained release, not for immediate effect. Pharmacokinetic studies show that the maximum concentration of the drug in the bloodstream is typically reached 9 to 12 hours after the initial patch application.

Q: Does Bremax affect sleep patterns?

Yes, the official drug information lists insomnia (difficulty falling or staying asleep) as one of the commonly reported adverse reactions. This is a recognized potential side effect that may occur during treatment initiation.

Q: How long after taking Bremax can I drive or operate machinery?

Official summaries note that the occurrence of certain side effects could potentially affect the ability to safely perform tasks like driving or operating heavy machinery. These specific side effects include tremors or palpitations.

Q: Is Bremax known to cause changes in mood or anxiety?

Regulatory documents list anxiety as a potential adverse reaction associated with the medicine. However, the incidence or frequency of this specific effect is not always known based on the clinical data summaries.

Q: Are there any specific warning signs I should look for when starting Bremax?

Official product information describes specific signs that may warrant immediate medical review. These include symptoms related to a severe allergic reaction, such as difficulty breathing or hives. Additionally, signs of a serious reduction in serum potassium, such as muscle weakness or difficulty breathing, are described in the regulatory information.

Q: Does Bremax require any special monitoring or blood tests?

Regulatory warnings note the potential risk of a serious reduction in serum potassium levels, known as hypokalemia. Due to this risk, medical oversight and monitoring for related signs is indicated, particularly muscle weakness and breathing difficulty.

Q: What is the purpose of the black box warning on Bremax's label?

According to available regulatory documents, the Tulobuterol transdermal patch does not carry a Black Box Warning. This type of warning is the strongest caution issued by some regulatory bodies to alert the public and prescribers to serious risks.

Q: Can Bremax affect fertility or family planning?

Official patient information states that the medicine's effect on fertility has not been established. Individuals with concerns about family planning may wish to review this specific matter with a healthcare provider.

How should Bremax be stored and disposed of?

How to Store and Dispose of Bremax

Official labeling requires specific conditions for the storage, handling, and disposal of Bremax to maintain stability and safety.

Requirement	Official Instruction
Storage Temperature	Store in a refrigerator (2 C to 8 C).
Protection & Handling	Keep in the original carton to protect from light. Do not freeze. Keep the bottle tightly closed.
Shelf Life	Unopened: 3 years. After first opening: Use within 3 months (when stored refrigerated).
Child Safety	Keep this medicine out of the sight and reach of children.
Disposal	Do not dispose of Bremax via wastewater or household waste. Consult a pharmacist for proper disposal methods to help protect the environment.